Price
$6.96+114.81%Social Signal Score
Analyst Ratings
11 analystsRevenue
$34.52M+676.38%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Garo H. Armen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 81
- Beta
- 1.55
- Country
- US
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- -14.24
Financials
Revenue
$34.52M+676.4%Net Income
$-550.0KEBITDA
$15.19MFree Cash Flow
$-31.20MEPS (diluted)
$-0.01Shares Outstanding (diluted)
41.34M+848.0%Operating Expenses
$23.23MCash & Debt
$18.74MReturn of Capital
$27.0KRevenue by Segment (annual)
$109.62MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $114.20M | $115.0K | $-0.00 |
| 2024 | $103.46M | $-227.21M | $-10.59 |
| 2023 | $156.31M | $-245.76M | $-13.75 |
| 2022 | $98.02M | $-220.07M | $-15.64 |
| 2021 | $295.67M | $-23.93M | $-2.11 |
| 2020 | $88.17M | $-180.91M | $-21.00 |
| 2019 | $150.05M | $-107.66M | $-22.10 |
| 2018 | $36.78M | $-159.69M | $-28.83 |
| 2017 | $42.88M | $-120.69M | $-24.53 |
| 2016 | $22.57M | $-127.00M | $-29.17 |
| 2015 | $24.82M | $-87.88M | $-22.47 |
| 2014 | $6.98M | $-42.49M | $-14.22 |
| 2013 | $3.04M | $-30.07M | $-2.21 |
| 2012 | $15.96M | $-11.32M | $-0.48 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $0.01
- Implied price
- $0.10
- Return from $8.71
- -58.9% a year
To earn 15.0% a year on these assumptions you'd need to buy at $0.05 — -99.4% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | -65.6% | -64.0% | -62.7% | -61.5% | -60.5% |
| 3.0% | -63.8% | -62.2% | -60.8% | -59.6% | -58.5% |
| 8.0% | -62.1% | -60.4% | -58.9% | -57.6% | -56.5% |
| 13.0% | -60.3% | -58.5% | -57.0% | -55.6% | -54.4% |
| 18.0% | -58.6% | -56.7% | -55.1% | -53.7% | -52.4% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+25.00%Social Signal Score
Mentions (5)
- Newsbusinesswire.com·2d ago·Neutral
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #AGEN--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus' multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus' anti-PD-1 a…
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript Agenus Inc. (AGEN) Shareholder/Analyst Call Transcript
View source ↗ - Newsbusinesswire.com·36d ago·Neutral
Agenus to Participate in Upcoming September Investor Conferences LEXINGTON, Mass.--(BUSINESS WIRE)---- $AGEN #BOT--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that Robin Taylor, Ph.D., Chief Commercial Officer, and Zack Armen, Head of Corporate Development and Investor Relations, will participate in fireside chats and one-on-one investor meetings at two upcoming investor conferences in September. Cantor Global Healthcare Conference 2026 September 9 -11, 20…
View source ↗ - Newsbusinesswire.com·39d ago·Positive
…nking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the peer-reviewed publication of mature Phase 1b results from the fully enrolled C-800-01 cohort evaluating botensilimab (BOT), a multifunctional Fc-enhanced anti–CTLA-4 antibody, plus balstilimab (BAL), an anti–PD-1 antibody, in 123 heavily pre-treated patients with mic…
View source ↗ - Newszacks.com·59d ago·Negative
Agenus (AGEN) Reports Q2 Loss, Tops Revenue Estimates Agenus (AGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of $0.05. This compares to a loss of $1 per share a year ago.
View source ↗
Earnings
Mon, Nov 9(in 5 weeks)
Consensus estimate $0.02 per share
Typical surprise -26.2% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.01 vs $0.04miss
- Mon, May 11$1.02 vs $2.10miss
- Mon, Mar 16$0.56 vs $-1.27beat
- Mon, Nov 10$1.94 vs $2.63miss
- Mon, Aug 11$-1.00 vs $-0.78miss
- Mon, May 12$-1.03 vs $-1.61beat
Estimates and results for AGEN via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by AGEN officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in AGEN.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.